Aggressive non-Hodgkin’s lymphoma: T-cell versus B-cell. Liang R,Todd D,Ho FC. Hematological Oncology . 1996Liang R, Todd D, Ho FC. Aggressive non-Hodgkin's lym- phoma: T-cell versus B-cell. Hematol Oncol 1996; 14: 1-6Liang R,,Todd D,Ho FC.Aggressive non-Hodgkin‘s lymphoma:...
The redirection of T cells has emerged as an attractive therapeutic principle in B cell non-Hodgkin lymphoma (B-NHL). However, a detailed characterization of lymphoma-infiltrating T cells across B-NHL entities is missing. Here we present an in-depth T cell reference map of nodal B-NHL, base...
B-cell maturation antigen (BCMA) is expressed in most cases of MM. We conducted the first-in-humans clinical trial of chimeric antigen receptor (CAR) T cells targeting BCMA. T cells expressing the CAR used in this work (CAR-BCMA) specifically recognized BCMA-expressing cells. Twelve ...
当然，为了治疗更为精准有效，干预不同类型的血液系统恶性肿瘤需要根据不同的肿瘤抗原，制备不同的免疫治疗产品，比如B细胞淋巴瘤（B cell leukemia/lymphoma）需要制备CD19，骨髓瘤（myeloma）需要制备BCMA，T细胞淋巴瘤（T cell leukemia/lymphoma）需要制备CD7，急性白血病（acute myeloid leukemia）需要制备CD33。虽然上...
2016年Ali等首次报道抗B细胞成熟抗原(B cell maturation antigen,BCMA) CAR-T细胞用于复发难治性多发骨髓瘤(relapse/refractory multiple myeloma,RRMM) 患者,初步证实有效性和安全性。随后国内外开展了大量抗BCMA CAR-T 细胞治疗 RRMM 临床研究,总有效率达73%~100%。CRS发生...
9. Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 2017;377:2531–2544. doi: 10.1056/NEJMoa1707447. - DOI - PMC - PubMed 10. Maude SL, et al. Tisagenlecleucel in children and young adults with B-cell ...
Kamdar M, Solomon SR, Arnason J, et al; TRANSFORM Investigators. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with...
Immune checkpoint inhibitors (ICIs), by reinvigorating CD8+ T cell mediated immunity, have revolutionized cancer therapy. Yet, the systemic CD8+ T cell distribution, a potential biomarker of ICI response, remains poorly characterized. We assessed safety,
First, as the function of TdT is to add N-nucleotides to the V-D-J junctions during recombination of the TCR and B-cell receptor9, its expression is confined to the B and T lineages. Second, TdT is overexpressed in 80–94% of ALL and lymphoblastic lymphoma of B- and T-cell origin...
Chow V A, Shadman M, Gopal A K. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma[J]. Blood, 2018, 132(8): 777-781. Abramson J S. Anti-CD19 CAR T...